Apellis Pharma's stock experienced a significant rise following a partnership with Biogen, sparking investor interest in the biotech sector. The deal highlights ongoing collaboration trends in pharmaceutical innovation.
- Apellis Pharma's stock surges on Biogen deal
- Event is a corporate action with moderate impact
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.
Share this article